Video Center


The OBR Video Center Features educational videos covering a wide range of oncology specific topics.

Robert Rifkin, MD, explains whether or not anti-BCMA CAR-T cell therapy looks promising

Dr. Rifkin, Hematologist/Oncologist, Associate Chair, US Oncology Hematology Research, Rocky Mountain Cancer Centers, explains whether or not anti-BCMA CAR-T cell therapy looks promising as a treatment for multiple myeloma patients

Tags: ASH Conference CoverageImmuno-oncology (includes cancer vaccines)Multiple Myeloma

Published: 07 December 2018

Recent Videos: Immuno-oncology (includes cancer vaccines)

There have been no new videos in this category within the last 12 months.

Related Videos

video-image

Kashyap Patel, MD, regarding two-sided risk and participation in the OCM

video-image

Stephen Schleicher, MD, MBA, discusses participation in the Oncology Care Model

video-image

Russell Gollard, MD, offers opinion on why IDNs are a cancer delivery model of the future

video-image

Russell Gollard, MD, considers the difference between a hospital and a non-hospital IDN

video-image

Russell Gollard, MD, considers the main impediments to coordinated care

video-image

Russell Gollard, MD, explains how IDNs effectively coordinate cancer care

video-image

Andrew Hertler, MD, FACP, on measuring success in value-based cancer care delivery

video-image

Andrew Hertler, MD, FACP, offers advice to oncology practices entering the value-based world

video-image

Andrew Hertler, MD, FACP, considers the benefits of participating in an ACO

video-image

Chadi Nabhan, MD, MBA, regarding the risks related to two-sided payment agreements

video-image

Chadi Nabhan, MD, MBA, elaborates on the skepticism regarding MACRA

video-image

Frederick Locke, MD, on whether CAR-T therapies will be expanded into solid tumors

video-image

Frederick Locke, MD, on the management of toxicity withs with CAR-T therapies

video-image

Julie Vose, MD, on management of common toxicities with CAR-T therapies

video-image

Frederick Locke, MD, on what improvements to turn around time with CAR-T therapies

video-image

Ted Okon, MBA, speculates on the path forward regarding 340B policy

video-image

Ted Okon, MBA, on the impact of the reduction in reimbursement for hospitals participating in 340B

video-image

Jeff Mortier speculates on the future of 340B policy

video-image

Jeff Mortier considers how 340B is impacting community oncology

video-image

Fred Schnell, MD, explains what COA is doing to help practices succeed in the OCM

video-image

Suanne Gersdorf, FACHE, MSB, shares how 340B has impacted her practice

video-image

Melissa Johnson, MD, on how Next Generation Sequencing is relevant to the treatment of NSCLC

video-image

Melissa Johnson, MD, discusses combinations and the treatment of lung cancer

video-image

Jennie Crews, MD, MMM, FACP, on the influence of MIPS & MACRA at Seattle Cancer Care Alliance

video-image

Satish Shah, MD, on how technology can ease the burden of reporting quality measures

video-image

Kavita Patel, MD, MS, FACP, discusses how 340B has impacted her practice

video-image

Kavita Patel, MD, MS, FACP, regarding the impact of MACRA on payment reform

video-image

Stephen Grubbs, MD, considers how MIPS & MACRA are transforming the delivery of cancer care

video-image

Stephen Grubbs, MD, describes the tools ASCO provides to help practices move toward value-based care

video-image

Stephen Grubbs, MD, on what ASCO is doing to help educate members about MIPS & MACRA

video-image

Bobby Green, MD, analyzes the role of health technology companies in the design of APMs

video-image

Ann Marie Edwards on how patients have been impacted by value-based care

video-image

Ann Marie Edwards tells us how technology has impacted the delivery of value-based care

video-image

Ann Marie Edwards examines how 340B has impacted Alliance Cancer Specialists

video-image

Ann Marie Edwards considers the physician practice models poised to succeed in a value-based world

video-image

George Daneker, MD, on the role of CMS and commercial payers in delivering value-based care

video-image

George Daneker, MD, regarding the role of consistency in the delivery of high-quality care

video-image

Jennie Crews, MD, MMM, FACP, on embracing new value-based oncology models

video-image

Jennie Crews, MD, MMM, FACP, explains how to maintain the delivery of quality cancer care

video-image

Sibel Blau, MD, discusses how 340B has impacted Northwest Medical Specialties

video-image

Sibel Blau, MD, shares how her practice has transformed in order to participate in MACRA

video-image

Roy Beveridge, MD, regarding the most cost-efficient alternative payment models

video-image

Alan Venook, MD, considers how immunotherapy is being integrated into CRC treatment algorithms

video-image

Parameswaran Hari, MD, MRCP, MS, on promising cellular immunotherapy studies from ASH 2017

video-image

Parameswaran Hari, MD, MRCP, MS, on how the field of immunotherapy is evolving for MM patients

video-image

Sandip Patel, MD, discusses some solutions for managing toxicities associated with immunotherapies

video-image

Sandip Patel, MD, considers immunotherapy combinations and the likelihood of severe adverse events

video-image

Sandip Patel, MD, on identifying patient types likely to experience immune-related adverse events

video-image

Sandip Patel, MD, describes the prominent safety challenges with administration of immunotherapies

video-image

Sandip Patel, MD, on the role of immunotherapies when treating cancer near end of life

video-image

Practical Issues When Treating With Immunotherapy

video-image

Beyond PD-L1: In Search of Better Biomarkers

video-image

Evolving Immunotherapy Combinations

video-image

Mary Jo Fidler, MD, FASCO, comments on the outlook for immunotherapy combinations in SCLC

video-image

Mary Jo Fidler, MD, FASCO, offers opinion on integrating immunotherapies into treatment of SCLC

video-image

Jeffrey Meyerhardt, MD, on how immunotherapies are being studied in gastric & esophageal cancers

video-image

Howard Hochster, MD, explains the impact of immunotherapies on gastric GE junction cancers

video-image

Patricia Goldsmith shares what CancerCare is doing to help patients with financial toxicity

video-image

Barbara Burtness, MD, discusses immunotherapies and treatment of head and neck cancers

video-image

Phil Bonomi, MD, on immunotherapy for treatment of SCLC and mesothelioma

video-image

Noa Biran, MD, shares how immunotherapies are being integrated into MM treatment algorithms

video-image

Jack West, MD, discusses possible immunotherapy combination treatments in the near future

video-image

Jack West, MD, on anti-PD-L1/PD-1 therapy in combination with chemotherapy & targeted therapies

video-image

Nicholas J. Vogelzang, MD, FASCO, FACP, speculates on the cost implications of abiraterone

video-image

Debu Tripathy, MD, on immunotherapies being studied for treatment of metastatic breast cancer

video-image

Randall Oyer, MD, describes how ACCC is supporting practices that are participating in OCM

video-image

Randall Oyer, MD, reveals the challenges and solutions his practice is finding as a result of OCM

video-image

Randall Oyer, MD, shares major themes emerging from the OCM

video-image

Randall Oyer, MD, on how OCM is helping the healthcare system transition from volume to value

video-image

Mohammad Jahanzeb, MD, FACP, on immunotherapy and treatment of metastatic breast cancer

video-image

Leonard Saltz, MD, elaborates on what interventions could help alleviate financial toxicity

video-image

Leonard Saltz, MD, on how to begin the conversation with patients about financial toxicity

video-image

Philip Philip, MD, considers the benefits of immunotherapy in treating gastrointestinal cancer

video-image

Andrew Pecora, MD, FACP, CPE, on the implications of healthcare and reimbursement reform

video-image

Andrew Pecora, MD, FACP, CPE, describes the movement to value-based reimbursement

video-image

Andrew Pecora, MD, FACP, CPE, on healthcare reform and the move from volume to value in oncology

video-image

Debra Patt, MD, MPH, MBA, speculates on upcoming changes in the 340B program

video-image

Sundar Jagannath, MD, on immunotherapies and multiple myeloma treatment algorithms

video-image

Lucio Gordan, MD, shares his concerns with PBMs as they affect community oncology practices

video-image

David Eagle, MD, shares how his small practice is successful in today’s oncology environment

video-image

David Eagle, MD, compares the rate of oncology spending to rate of total healthcare spending

video-image

David Eagle, MD, evaluates what part of total oncology care spending is drug spending

video-image

Joseph Lynch, MD, on why independent community oncology practices join hospital systems

video-image

Skip Burris, MD, shares how clinical pathways impact prescribing decisions

video-image

Skip Burris, MD, on the impact of OCM on large community practices

video-image

Bruce Feinberg, DO, on what community oncologists should consider with MACRA, MIP’s and OCM

video-image

Jeff Patton, MD, shares how clinical pathways help with value-based efforts

video-image

Jeff Patton, MD, on whether the Oncology Care Model impacts the prescribing of oral cancer agents

video-image

Jeff Patton, MD, explains how Tennessee Oncology has transformed to participate in OCM

video-image

Lucio Gordan, MD, considers how 340B is impacting physicians and practices

video-image

Robert Baird Jr. reflects on how his practice has changed as a result of OCM

video-image

Edward Li on how clinical pathways are making progress towards their original goals

video-image

Edward Li reflects on how pathways have impacted oncology treatment over the last 5 years

video-image

Ted Okon lists key takeaways from the 2017 COA meeting

video-image

Ted Okon describes how PBMs affect oncologists and cancer patients

video-image

Ted Okon shares the latest news on the 340B policy

video-image

Ben Jones gives advice to practices interested in advocating for community oncology

video-image

Lalan Wilfong, MD, shares lessons from his experience participating in OCM

video-image

Lalan Wilfong, MD, explains how OCM has impacted cancer patients in his practice

video-image

Lalan Wilfong, MD, provides opinion on how OCM is changing his practice

video-image

Debra Patt, MD, considers how community oncology contributes to clinical research advancement

video-image

Debra Patt, MD, on technological advances in cancer care and community oncology

video-image

Debra Patt, MD, shares how community oncology has contributed to advances in population health

video-image

Debra Patt, MD, elaborates on how community oncology contributes to the Cancer Moonshot

video-image

Jeff Vacirca, MD, shares how COA is addressing the DIR fees coming from PBMs

video-image

Jeff Vacirca, MD, on COA’s efforts to represent community oncologists

video-image

Jeff Vacirca, MD, discusses DIR fees and how COA hopes to solve the PBM fee problem

video-image

Jeff Vacirca, MD, on how COA is addressing Part B concerns among community oncologists

video-image

Lucio Gordan, MD, on how community oncology practices can utilize their own data

video-image

Lucio Gordan, MD, reflects on how he sees community oncology using big data

video-image

Matt Farber provides insight on the evolution of specialty pharmacies

video-image

Matt Farber explains the role of specialty pharmacy in delivering quality cancer care

video-image

David Eagle, MD, compares small, community oncology practices with large practices and hospitals

video-image

Ray Bailey on how participation in OCM impacts the in-house pharmacy at FCS

video-image

Patrick Cobb, MD, on cancer care costs in hospital outpatient and community settings

video-image

Brad Prechtl offers his opinion on how size influences community oncology practices

video-image

William Harwin, MD, on how clinical pathways impact treatment decisions at FCS

video-image

William Harwin, MD, explains how he manages the quality measures required for OCM

video-image

William Harwin, MD, on working with local payers to deliver quality care

video-image

William Harwin, MD, talks changes at Florida Cancer Specialists since participating in OCM

video-image

Barbara McAneny, MD, discusses 1 sided and 2 sided risk associated with participation in the OCM

video-image

Barbara McAneny, MD, shares her concerns with the way OCM is progressing at this point

video-image

Ricky Newton tells us how COA is addressing the PBM DIR fees and helping community oncology

video-image

Bobby Green, MD, on how oncologists can leverage data to understand real quality care

video-image

Barbara McAneny, MD, explains how the AMA and community oncology should interact

video-image

Mohamad E. Allaf, MD, on immunotherapies and renal cell carcinoma treatment algorithms

video-image

Eric Jonasch, MD, on integrating immunotherapies into renal cell carcinoma treatment algorithms

video-image

Ana Aparicio, MD, on immunotherapy as a future treatment guideline for metastatic prostate cancer

video-image

Nicholas J. Vogelzang, MD, FASCO, FACP, on immunotherapy and metastatic prostate cancer

video-image

Aly-Khan Lalani, MD, offers feedback on using immunotherapies to treat renal cell carcinoma patients

video-image

Nicholas J. Vogelzang, MD, FASCO, FACP, on BRCA1 and BRCA2 genetic testing as guidelines

video-image

Aly-Khan Lalani, MD, examines the integration of immunotherapies for renal cell carcinoma treatment

video-image

Charles Saunders, MD, on the operational changes necessary to succeed in a value-based environment

video-image

Charles Saunders, MD, considers EHR providers in an era of value-based care

video-image

Charles Saunders, MD, discusses how value-based care is driving technology innovation in oncology

video-image

Neal D. Shore, MD, FACS, on BRCA1 and BRCA2 genetic testing as guidelines for prostate cancer

video-image

Maddy Herzfeld, discusses the challenges practices are facing when implementing patient engagement

video-image

Maddy Herzfeld, on solutions available for practices to implement better patient engagement

video-image

Maddy Herzfeld, on how oncology practices consume patient-reported data to improve patient care

video-image

Marcus Neubauer, MD, explains how clinical pathways save money when treating cancer

video-image

Marcus Neubauer, MD, discusses if clinical pathways create value in cancer care

video-image

Marcus Neubauer, MD, explains how clinical pathways differ from clinical guidelines

video-image

Marcus Neubauer, MD, discusses how practices and administrators can build higher pathway compliance

video-image

Mike Kolodziej, MD, explains the impact of the ACA on the insurance industry

video-image

Mike Kolodziej, MD, talks about how CMMI is changing the health care system

video-image

Mike Kolodziej, MD, discusses how technology is helping reform the way practices operate

video-image

Mike Kolodziej, MD, on how the clinical data set at Flatiron helps oncologists

video-image

Mike Kolodziej, MD, explains how Flatiron analytics help practices succeed in value based care

video-image

Ed Bassin, Ph.D., on what oncologists should be thinking about as they approach value based care

video-image

Ed Bassin, Ph.D., on working with hospital-based cancer centers vs community practices

video-image

Ed Bassin, Ph.D., on if there will be health care savings with the implementation of the OCM

video-image

Ed Bassin, Ph.D., explains the challenges for oncologists and practices with the OCM model

video-image

Ira Klein, MD, discusses how limited distribution impacts the delivery of oral cancer agents

video-image

Diana Verrilli, McKesson Specialty Health, on how claims data is being used

video-image

Diana Verrilli, McKesson Specialty Health, on how claims data can be used in the OCM model

video-image

Steve D’Amato, R.Ph., talks about what technology his practice adopted to participate in OCM

video-image

Steve D’Amato, R.Ph., on why this is a challenging time for oncology practices

video-image

Steve D’Amato, R.Ph., on whether the ACA changed access to care at New England Cancer Specialists

video-image

Jeffrey Scott, MD, shares the highest-impact areas of focus for value-based care savings

video-image

Jeffrey Scott, MD, on how important the drug channel is compared to reduction in hospitalizations

video-image

Jeffrey Scott, MD, discusses best practices for a GPO to help with value-based savings

video-image

Jeffrey Scott, MD, explains his vision for how GPOs must evolve in the era of value-based care

video-image

Dave Terry, Chief Executive Officer, on the keys to success when participating in APMs

video-image

Dave Terry, Chief Executive Officer, shares his thoughts on Alternative Payment Models of the future

video-image

Dave Terry, Chief Executive Officer, explains why practices should participate in APMs

video-image

Debra Patt, MD, explains how data systems help with patient care delivery in community oncology

video-image

Linda Bosserman, MD, explains what MACRA means for oncologists today

video-image

Linda Bosserman, MD, discusses the highlights of the MACRA panel at CCBS 2017

video-image

Lili Brillstein, M.P.H., explains the primary goal of an episode of care

video-image

Lili Brillstein, M.P.H., explains how an episode of care is different from a bundled payment

video-image

Harlan Levine, MD, on the philosophy for establishing quality metrics as they relate to an ACO

video-image

James Hamrick, MD, on using real world evidence to learn how to treat cancer patients

video-image

Lili Brillstein, M.P.H., shares her thoughts on the keys to success to make episodes of care work

video-image

Lili Brillstein, M.P.H., explains the requirements that must be met in an episode assessment

video-image

Harlan Levine, MD, on treating patients in this era of high cost cancer drugs

video-image

Harlan Levine, MD, on how cancer care navigators impact quality of care at City of Hope

video-image

James Hamrick, MD, explains how EMRs help connect patients and caregivers

video-image

Debra Patt, MD, explains how decision support tools improve the quality and delivery of cancer care

video-image

Debra Patt, MD, explains using predictive analytics to improve cancer care delivery

video-image

Linda Bosserman, MD, explains “Pick Your Pace” as it relates to participation in MACRA

video-image

Linda Bosserman, MD, on deciding whether to participate in MIPS or AAPM

video-image

Alan P. Venook, MD, explains how the 80405 study and its impact on treatment guidelines

video-image

Chadi Nabhan, MD, on payers using clinical pathways in hematological malignancies vs solid tumors

video-image

Chadi Nabhan, MD, on incorporating clinical pathways into CLL and other hematologic malignancies

video-image

David Ettinger, MD, talks about impact of immunotherapy in 1st line metastatic NSCLC patients

video-image

Julie Gralow, MD, shares perspective on the evolving development immunotherapies in breast cancer

video-image

Alexander Perl, MD, on the role of immunotherapy in treating hematological malignancies

video-image

Tanios Bekaii-Saab, MD, on progress in developing immunotherapies in non MSI- High CRC patients

video-image

David Gandara, MD, discusses considerations when choosing between immunotherapy and chemotherapy

video-image

David Gandara, MD, discusses PD-L1 expression and selecting the appropriate agent in NSCLC patients

video-image

Bert O’Neill, MD, on making immunotherapy more effective in mCRC

video-image

Jennie R. Crews, MD talks about the goals of the ICLIO as developed by ACCC

video-image

Mark Levis, MD, discusses the role of immunotherapy in treating hematological malignancies

video-image

Eunice S. Wang, MD, on immunotherapy and its potential role in treating hematological malignancies

video-image

David Ettinger, MD, on choosing between immunotherapy and chemotherapy in metastatic NSCLC patients

video-image

David Ettinger, MD, talks about levels of PD-L1 expression and agent selection

video-image

Aref Al-Kali, MD, on immunotherapy and its potential role in treating hematological malignancies

video-image

Anthony El-Khoueiry, MD, talks results of nivolumab (Opdivo) trial in Hepatocellular Carcinoma (HCC)

video-image

Jennie R. Crews, MD relays the unique side effects being seen with long-term use of immunotherapies

video-image

Jennie R. Crews, MD, explains if there is a stopping point where immunotherapy shouldn’t be used

video-image

Jennie R. Crews, MD, looks at long-term efficacy with immunotherapies

video-image

Jennie R. Crews, MD, discusses the broad applicability and limitations with immunotherapy

video-image

Jeffrey Weber, MD, PhD explains the importance of testing for NRAS as compared with a BRAF Biomarker

video-image

Jeffrey Weber, MD, PhD discusses the response rates and PFS for longer OS based on immunotherapies

video-image

Jeffrey Weber, MD, PhD discusses the long term side effects with immunotherapies

video-image

Jeffrey Weber, MD, PhD, discusses the efficacy of checkpoint inhibitors and immunotherapy

video-image

Jeffrey Weber, MD, PhD explains the importance of administering ipilimumab with a PD-L1 inhibitor

video-image

Jeffrey Weber, MD, PhD provides interpretation of the NEMO trial results

video-image

Debu Tripathy, MD provides update on breast cancer treatment algorithms impacted by PD-L1

video-image

Jeffrey A. Meyerhardt, MD, discusses immunotherapy in MSI-Stable CRC patients

video-image

Laura Chow, MD discusses incorporating checkpoint inhibitors into standard of care

video-image

Barbara Burtness, MD explains if the Keynote-012 study confirms the benefit seen with Keytruda

video-image

Richard Goldberg, MD, talks patient response with the combination of MEK and PD-1 inhibitors

video-image

Bert O'Neil, MD and the combination of ipilimumab with nivolumab in mCRC patients

video-image

Alexander Lesokhin, MD discusses the development of immunotherapies for multiple myeloma patients

video-image

Alan Venook, MD discusses development of immunotherapies for non MSI-High CRC patients

video-image

Charles Bane, MD, touches on the COME HOME project while discussing the Oncology Care Model

video-image

Charles Bane, MD, touches on the COME HOME project while discussing the Oncology Care Model

video-image

Charles Bane, MD, discusses the practicality of the value tool at Dayton Physicians Network

video-image

Perspective on the NCCN Evidence Blocks by Charles Bane, MD

video-image

Perspective on the ASCO Value Framework by Charles Bane, MD

video-image

Bruce Gould, MD, explains how the value tools could be used in the community practice setting

video-image

Perspective on the NCCN Evidence Blocks provided by Bruce Gould, MD

video-image

Perspective on the ASCO Value Framework provided by Bruce Gould, MD

video-image

Bruce Gould, MD, explains ASCO’s policy toward clinical pathways at this time

video-image

The impact of clinical pathways on quality cancer care as explained by Bruce Gould, MD

video-image

Bruce Gould, MD, describes the concerns his practice has with clinical pathways

video-image

Barbara McAneny, MD, explains why CMS implemented the ASP experiment

video-image

Barbara McAneny, MD, informs as to what practices should know about MACRA

video-image

Barbara McAneny, MD, reviews the COME HOME project’s influence on the Oncology Care Model

video-image

Barbara McAneny, MD, discusses COME HOME’s adaptability to other community oncology practices

video-image

Barbara McAneny, MD, talks about the COME HOME project’s impact on community oncology practices

video-image

Barbara McAneny, MD, discusses the COME HOME project’s future

video-image

Jeff Patton, MD, explains what could happen if the CMS ASP Experiment proceeds as planned by CMS

video-image

Jeff Patton, MD, explains how Tennessee Oncology benefits from being a member of COA

video-image

Jeff Patton, MD, explains why the 2016 COA meeting is a must attend meeting

video-image

Jeff Patton, MD, discusses his new role with the Community Oncology Alliance (COA)

video-image

Deborah Patt, MD, shares her concerns about the CMS ASP Experiment and Part B reimbursement

video-image

Deborah Patt, MD, tells us how chemotherapy costs figure into total care

video-image

Deborah Patt, MD, points out how oncologists can reduce cancer costs

video-image

Deborah Patt, MD, details surprising outcomes from a recent cost study

video-image

Deborah Patt, MD, looks at the bigger expense drivers in cancer care

video-image

David Eagle, MD, gives his opinion on the CMS ASP Experiment

video-image

David Eagle, MD, enumerates what oncologists can do to bring cancer costs down

video-image

David Eagle, MD, lists outcomes from the COA study surprising to oncologists

video-image

David Eagle, MD, details the bigger expenses driving up cancer care costs based on the COA study

video-image

David Eagle, MD, compares costs for treating cancer vs. non-cancer based on the COA study

video-image

David Eagle, MD, talks about COA’s Cost Drivers of Cancer Care study

video-image

Bhuvana Sagar, MD, tells us about the Cigna medical home for oncologists

video-image

Bhuvana Sagar, MD, discusses Cigna’s work with oncologists to find alternative payment models

video-image

Bhuvana Sagar, MD, explains the need for alternative payment models in oncology

video-image

Barry Russo explains the impact of the CMS ASP Experiment

video-image

Practices need to get ready to replace buy and bill explains Barry Russo

video-image

Bruce Gould, MD, explains the characteristics that makes a practice ready for OCM

video-image

Brad Prechtl briefs us on his concerns with the“Medicare Experiment” and its impact

video-image

Brad Prechtl tells how his practice is working to improve cancer care

video-image

Brad Prechtl talks about how community oncology practices can survive today

video-image

Brad Prechtl explains the benefits of community oncology practices joining forces

video-image

Bhuvana Sagar, MD, forecasts the possible Cigna adoption of a Medicare OCM model

video-image

Participation in the Oncology Care Model (OCM) as explained by Barry Russo

video-image

Barry Russo explains how important it is to embrace alternative payment models

video-image

Barry Russo tells us how his practice is getting ready for value-based care

video-image

Patrick Cobb, MD, FACP, looks ahead to treatment innovations that will make a difference

video-image

Patrick Cobb, MD, FACP, talks about some exciting, recent innovations in cancer treatment

video-image

Michael Diaz, MD, talks about working with payers to add quality and value

video-image

Michael Diaz, MD, discusses the challenges in adopting quality and value measures

video-image

Michael Diaz, MD, talks about why the community oncology setting is the best value for patients

video-image

John Fox, MD, predicts if the ASCO Value Framework or NCCN Evidence Blocks will impact drug spend

video-image

John Fox, MD, talks about how Priority might use the ASCO and NCCN value tools

video-image

John Fox, MD, talks about the new value tools from ASCO and NCCN

video-image

John Fox, MD, provides perspective on collaborating with providers on clinical pathways

video-image

A look at cancer clinical pathways with Charles Bane, MD

video-image

Ricky Newton, CPA, updates us on COPA

video-image

Ricky Newton, CPA, details how COPA’s website helps practice managers, pharmacists, and patients

video-image

Ricky Newton, CPA, explains the purpose of COPA’s new In-House and Specialty Pharmacies brief

video-image

Ricky Newton, CPA, tells us what follow up to expect from COPA’s new brief

video-image

Robert Baird fills us in on the Value-Based Purchasing Modifier's impact on Dayton

video-image

Robert Baird details how practices can prepare for the Value-Based Purchasing Modifier and MIPS

video-image

Robert Baird explains how Dayton physicians and payers are collaborating on APMs

video-image

Robert Baird answers questions on Dayton’s participation in the Oncology Care Model

video-image

Skip Burris, MD, outlines the scope of cancer clinical trials at SCRI

video-image

Skip Burris, MD, looks at the promise of immunotherapies in combination

video-image

Skip Burris, MD, explains goals and outcomes of the My Pathway trial

video-image

Skip Burris, MD, reflects on the promise and concerns with liquid biopsies

video-image

Ted Okon tells us why the CNS ASP Experiment is a bad idea

video-image

Embrace alternative payment models explains Ted Okon

video-image

Todd Murphree, PharmD, tells us how in-house dispensing in his practice benefits patients

video-image

Todd Murphree, PharmD, tells us how in-house dispensing in his practice benefits patients

video-image

Todd Murphree, PharmD, explains the role an in-house pharmacy plays in the quality equation

video-image

Sue Naeyaert predicts whether we will see more cancer biosimilars soon

video-image

Sue Naeyaert tells us what to expect in pricing biosimilars

video-image

A look at the expansion of a biosimilar’s FDA label with Sue Naeyaert

video-image

Sue Naeyaert explains the proposed reimbursement of biosimilars by CMS

video-image

Skip Burris, MD, discusses how precision medicine is changing cancer treatment

video-image

Sue Naeyaert provides her vision of the biosimilar products in development

video-image

Todd Murphree briefs us on ACHC’s oncology accreditation process

video-image

Todd Murphree, PharmD, discusses how ACHC accreditation benefits his practice

video-image

Ted Okon discusses the sessions that stand out at this year's annual meeting

video-image

Ted Okon discusses the 2016 Community Oncology Alliance annual meeting

video-image

Ted Okon discusses the 2016 Community Oncology Alliance annual meeting

video-image

Ted Okon provides an overview of the Cost Drivers in Cancer Care study

video-image

Mary Kruczynski speaks to those who were unable to attend the 2016 Annual COA meeting

video-image

Mary Kruczynski tells us how the 2016 Annual COA meeting benefits health care providers

video-image

Mary Kruczynski reflects on highlights from COA

video-image

Lucio Gordan, MD, lists takeaways from COA that can benefit his own practice

video-image

Lucio Gordan, MD, debriefs providers who didn’t attend on highlights from COA

video-image

Lucio Gordan, MD, reflects on key messages from this year’s COA

video-image

Jeff Vacirca, MD, explains the relevance of the COA/Milliman study to his practice

video-image

Jeff Vacirca, MD, talks about what his community oncology practice is doing to survive

video-image

Jeff Patton, MD, explains how his practice is working to develop alternative payment models

video-image

COA is helping community oncologists by fighting the CMS ASP Experiment by Jeff Patton, MD

video-image

Robert Baird tells us what MIPS are and how practices might use them

video-image

Patrick Cobb, MD, discusses treatment innovations and managing patient’s expectations

video-image

Jeff Vacirca, MD, shares his thoughts on the “Medicare Experiment” on community oncology

video-image

David Eagle, MD, compares treatment costs in different settings

video-image

Mary Kruczynski tells us how the Cost Drivers in Cancer Care study was developed

video-image

Michael Kolodziej, MD, describes the breadth and depth of alternative payment models

video-image

Michael Kolodziej, MD, tells us why alternative payment models are needed

video-image

Kavita Patel, MD, MS, explains how 340B is impacting cancer care

video-image

Kavite Patel, MD, MS, tells us whether ACOs are having an impact on oncologists

video-image

Michael Kolodziej, MD, discusses alternative payment models of the future

video-image

John Iacuone, MD, MBA, explains how practices stay independent in pay for performance environment

video-image

Bobby Green, MD, MSCE, explains the frustrations with data coming from oncology practices

video-image

Kavita Patel, MD, MS discusses how important cancer care management is to Medicare

video-image

William Harwin, MD, gives his opinion if practices can survive in today's value based environment

video-image

Immunotherapy, MET, and HER 2+ research is the future of colorectal cancer treatment ASCO GI 2016

video-image

John Sprandio, MD, explains how his practice worked with CMS to help develop the Oncology Care Model

video-image

Harold Miller discusses the barriers in the fee for service model

video-image

The future of gastric cancers will be targeted agents including immunotherapy

video-image

ASH 2015 Data Promises Immunotherapy Revolution in Multiple Myeloma with Pembrolizumab

video-image

Noa Biran, MD, considers the role of BCMA CAR-T cells in the management of multiple myeloma

video-image

Frederick Locke, MD, offers opinion regarding off-the-shelf CAR-T cell therapies

video-image

Noa Biran, MD, provides her impression of the Phase 3 ICARIA-MM study

video-image

Timothy Illidge, MD, PhD, describes the ECHELON-2 data presented at ASH 2019

video-image

Noa Biran, MD, explains how JNJ-4528 differs from other CAR-T products

video-image

Timothy Illidge, MD, PhD, explains the purpose of targeting peripheral t-cell lymphoma

video-image

Noa Biran, MD, tells us about the outcomes of the CARTITUDE-1 study

video-image

Ryan Lynch, MD, on how physicians should be thinking about BTK inhibitors in the treatment of CLL

video-image

Timothy Illidge, MD, PhD, shares the the primary and secondary endpoints of the ECHELON-2 study

video-image

Ryan Lynch, MD, offers his impressions of the Transcend-NHL data presented at ASH 2019

video-image

Timothy Illidge, MD, PhD, on the impact of the ECHELON-2 trial data

video-image

Ryan Lynch, MD, on whether MRD is a valid endpoint when measuring treatment efficacy in CLL

video-image

Ryan Lynch, MD, considers the ideal patient profile for zanubrutinib in RR-MCL

video-image

Christopher Yasenchak, MD, on the most impressive data in the treatment of Hodgkin’s lymphoma

video-image

Ryan Lynch, MD, tells us about the four-year update on the outcomes of the MURANO study

video-image

Chaitra Ujjani, MD, considers the ideal patient profile for zanubrutinib in RR-MCL

video-image

Angela Dispenzieri, MD, speculates on the the clinical impact of the TOURMALINE-AL1 study

video-image

Chaitra Ujjani, MD, considers how physicians should be thinking about BTK inhibitors in CLL

video-image

Angela Dispenzieri, MD, elaborates on the outcomes from the TOURMALINE-AL1 study

video-image

Chaitra Ujjani, MD, tells us about Veneto-STOP study presented at ASH 2019

video-image

Angela Dispenzieri, MD, shares the design of the TOURMALINE-AL1 study presented at ASH 2019

video-image

Jeffrey Sharman, MD, on the benefits of zanubrutinib as compared to other BTK inhibitors

video-image

Daniel Pollyea, MD, speculates on how oral HMAs will impact the landscape in myeloid malignancies

video-image

Jeffrey Sharman, MD, explains how we should be thinking about BTK inhibitors in the treatment of CLL

video-image

Daniel Pollyea, MD, provides opinion on current treatment strategies for elderly AML patients

video-image

Jeffrey Sharman, MD, shares updates from the CLL14 study presented at ASH 2019

video-image

Daniel Pollyea, MD, discusses prognostic factors in acute myeloid leukemia (AML) patients

video-image

Jeffrey Sharman, MD, tells us about the design and outcomes of the Phase 3 ELEVATE TN from ASH 2019

video-image

Daniel Pollyea, MD, discusses the most promising emerging strategies in the management of AML

video-image

Andre Goy, MD, considers whether off-the-shelf CAR-T cell therapies are becoming a reality

video-image

Daniel Pollyea, MD, elaborates on the evolving treatment landscape in myelodysplastic syndromes

video-image

Andre Goy, MD, on the TRANSCEND-CLL-004 data investigating the use of CAR-T cell therapy DLBCL

video-image

Jae H. Park, MD, on incorporating CAR-T cell therapies into acute leukemia treatment algorithms

video-image

Andre Goy, MD, discusses the three-year survival analysis of the ZUMA-1 study from ASH 2019

video-image

Jae H. Park, MD, on the factors associated with improved survival after CD19 CAR-T cell therapy

video-image

Andre Goy, MD, regarding the ZUMA-2 study investigating anti-CD19 CAR-T cell therapy MCL

video-image

Jae H. Park, MD, regarding combination vemurafenib and obinutuzumab in hairy cell leukemia patients

video-image

Constantine Tam, MBBS, MD, regarding the patient profile in MCL most suitable for zanubrutinib

video-image

Chaitra Ujjani, MD, tells us about the results of the Phase 3 ELEVATE TN study in CLL

video-image

Angela Dispenzieri, MD, expands on the side effects from the TOURMALINE-AL1 study

video-image

Amrita Krishnan, MD, elaborates on BCMA-directed strategies for multiple myeloma patients

video-image

Chaitra Ujjani, MD, offers her impression of the Phase 2 CAPTIVATE study in CLL

video-image

Amrita Krishnan, MD, tells us about the Phase 3 Dreamm-3 study presented at ASH 2019

video-image

David Andorsky, MD, defines RWE and explains how it compliments clinical trial results

video-image

Christopher Yasenchak, MD, on 1st line brentuximab vedotin + nivolumab in Hodgkin’s lymphoma

video-image

David Andorsky, MD, provides examples of how RWE has impacted the oncology community

video-image

Christopher Yasenchak, MD, tells us about the patient profile most suited for zanubrutinib in MCL

video-image

David Andorsky, MD, on the results of his RWE study investigating idelalisib in follicular lymphoma

video-image

Amrita Krishnan, MD, tells us about the outcomes of the CARTITUDE-1 study presented at ASH 2019

video-image

David Andorsky, MD, discusses the implications of real-world evidence for oncologists

video-image

Amrita Krishnan, MD, tells us about the results of the Phase 1 study investigating CC-93269 in MM

video-image

James Essell, MD, offers opinion on the future of off-the-shelf CAR-T cell therapy

video-image

Amer Zeidan, MBBS, considers RWE in older patients with acute myeloid malignancies

video-image

James Essell, MD, regarding off-the-shelf CAR NK cell therapy in treating B-cell malignancies

video-image

Amer Zeidan, MBBS, speculates on the role of immune checkpoint blockades in myeloid malignancies

video-image

James Essell, MD, offers his impression the data investigating the bi-specific CAR-T cell therapy

video-image

Amer Zeidan, MBBS, elaborates on the role of venetoclax in treatment of MDS

video-image

James Essell, MD, discusses the integration of stem cell transplantation in the treatment of myeloma

video-image

Amer Zeidan, MBBS, on the role of oral therapies in the treatment of myeloid malignancies

video-image

Constantine Tam, MBBS, MD, considers the role of CAR-T cell therapy in chronic lymphocytic leukemia

video-image

Peter M. Voorhees, MD, explains how daratumumab is changing the way MM patients are treated today

video-image

Constantine Tam, MBBS, MD, tells us about the Phase 2 CAPTIVATE study presented at ASH 2019

video-image

Peter M. Voorhees, MD, summarizes the outcomes of the Phase 2 Griffin study in newly diagnosed MM

video-image

Constantine Tam, MBBS, MD, compares the benefits of zanubrutinib to other BTK inhibitors

video-image

Shyamala Navada, MD, MSCR, discusses the treatment of elderly patients with myeloid malignancies

video-image

Constantine Tam, MBBS, MD, regarding the data that lead to the recent FDA approval of zanubrutinib

video-image

Sattva Neelapu, MD, tells us about the results of the ZUMA-1 study in DLBCL presented at ASH 2019

video-image

Shyamala Navada, MD, MSCR, offers opinion on how the treatment landscape of MDS is evolving

video-image

Sattva Neelapu, MD, considers whether off-the-shelf CAR-T cell therapy is becoming a reality

video-image

Constantine Tam, MBBS, MD, offers his impression of the Phase 2 CAPTIVATE study in CLL from ASH '19

video-image

Sattva Neelapu, MD, on the role of CAR NK cell therapy in the treatment of B-cell malignancies

video-image

Shyamala Navada, MD, MSCR, on how oral therapies will impact the treatment of myeloid malignancies

video-image

John Burke, MD, regarding tafasitamab or tafasitamab + lenalidomide in addition to R-CHOP in DLBCL

video-image

John Burke, MD, offers opinion on how physicians should be thinking about the use of BTK inhibitors

video-image

Robert Rifkin, MD, FACP, on whether medical oncologists are embracing therapeutic biosimilars

video-image

John Burke, MD, outlines the patient profile best suited for zanubrutinib in relapsed/refractory MCL

video-image

Robert Rifkin, MD, FACP, on the role of daratumumab as maintenance therapy in the management of MM

video-image

Luciano J. Costa, MD, PhD, offers opinion on whether MRD tests can help guide treatment decisions

video-image

Robert Rifkin, MD, FACP, offers opinion on the most promising studies in MM presented at ASH 2019

video-image

Luciano J. Costa, MD, PhD, explains how academic and community oncologists can utilize MRD tests

video-image

Courtney DiNardo, MD, provides opinion on current treatment strategies for elderly AML patients

video-image

Jasmine Zain, MD, shares outcomes from the PRIMO study investigating duvelisib in PTCL

video-image

Courtney DiNardo, MD, describes the targeted therapy landscape in acute myeloid leukemia

video-image

Jasmine Zain, MD, tells us about the novel approaches in development for the treatment of PTCL

video-image

Courtney DiNardo, MD, regarding the evolution of treatment in acute myeloid leukemia

video-image

Jasmine Zain, MD, discusses the most impressive studies in PTCL presented at ASH 2019

video-image

Courtney DiNardo, MD, considers the role of intensive chemotherapy in newly diagnosed AML

video-image

Jasmine Zain, MD, considers how peripheral T-cell lymphoma therapy has evolved in recent years

video-image

Max Topp, MD, on whether a risk management plan exists to help reduce toxicity of CAR-T cell therapy

video-image

Bruce Feinberg, DO, elaborates on how oncologists are utilizing real-world evidence today

video-image

John Seymour, MBBS, PHD, on whether MRD is a valid endpoint when measuring treatment efficacy in CLL

video-image

Bruce Feinberg, DO, provides examples of how RWE has impacted decision-making in oncology

video-image

John Seymour, MBBS, PHD, elaborates on the updated data from the Phase 3 MURANO trial

video-image

Bruce Feinberg, DO, defines and explains the role of real-world evidence

video-image

Kylee Martens, MD, compares rasburicase versus allopurinol in patients with hyperuricemia

video-image

Michael Wang, MD, regarding the pivotal clinical data that lead to the FDA approval of zanubrutinib

video-image

Michael Wang, MD, speculates on therapies for front-line and relapsed mantle cell lymphoma

video-image

Michael Wang, MD, on the distinct advantages of zanubrutinib in the management of lymphoma

video-image

Kylee Martens, MD, on the role of rasburicase in managing TLS in patients with renal dysfunction

video-image

Kylee Martens, MD, on those patient types more suited for treatment with rasburicase vs. allopurinol

video-image

Max Topp, MD, shares the long-term results of the ZUMA-1 trial presented at ASH 2019

video-image

Kylee Martens, MD, considers whether there are certain patient types more prone to TLS

video-image

Luciano J. Costa, MD, PhD, on whether minimal residual disease can be used to predict outcomes

video-image

Robert Rifkin, MD, FACP, tells us about the outcomes of the LYRA study presented at ASH 2019

video-image

Luciano J. Costa, MD, PhD, on how measurement of MRD is evolving as an endpoint in clinical trials

video-image

Catherine Diefenbach, MD, explains how combination therapies are evolving in follicular lymphoma

video-image

Joseph Alvarnas, MD, on seeking creative solutions to provide proper access to innovative therapy

video-image

Saro Armenian, DO, MPH, reflects on promising clinical innovations in the management of leukemia

video-image

Joseph Alvarnas, MD, on the challenges facing cancer centers when delivering innovative therapies

video-image

Saro Armenian, DO, MPH, considers the relevance of bone marrow transplant in leukemia & lymphoma

video-image

Catherine Diefenbach, MD, regarding the unmet needs in the management of follicular lymphoma

video-image

Saro Armenian, DO, MPH, on bone marrow transplant survivorship outcomes in AML patients

video-image

Michael Wang, MD, shares details from the ZUMA-2 trial in mantle cell lymphoma presented at ASH 2019

video-image

Joseph Alvarnas, MD, regarding CAR-T cell therapy in an era of value-based care

video-image

Catherine Diefenbach, MD, on the recent data investigating obinutuzumab in follicular lymphoma

video-image

Andrew Cowan, MD, elaborates on the role of isatuximab in the management of multiple myeloma

video-image

Joseph Alvarnas, MD, on how to responsibly integrate clinical innovations into treatment algorithms

video-image

Michael Jain, MD, offers his opinion on off-the-shelf CAR-T cell therapy

video-image

James McCloskey, MD, regarding the QUASAR-001 study presented at ASH 2019

video-image

Michael Jain, MD, shares the outcomes of the US CAR-T Cell Consortium study from ASH 2019

video-image

Andrew Cowan, MD, on the most promising clinical data in multiple myeloma presented at ASH 2019

video-image

James McCloskey, MD, considers how the role of molecular profiling in AML is changing

video-image

Michael Jain, MD, discusses how population-based outcomes in B-cell lymphomas are changing

video-image

Andrew Cowan, MD, provides an overview of the use of CAR-T cell therapy in multiple myeloma

video-image

James McCloskey, MD, speculates on the landscape of MDS as a result of data presented at ASH '19

video-image

Michael Jain, MD, offers perspective on the latest treatment trends for aggressive lymphomas

video-image

James McCloskey, MD, shares his impression of the Phase 3 ASCERTAIN trial in MDS

video-image

Andrew Cowan, MD, discusses the role of human BCMA CAR-T cells in the management of multiple myeloma

video-image

Michael Jain, MD, regarding CAR-natural killer (NK) cell therapy

video-image

Lori Leslie, MD, on real-world evidence regarding CAR-T cell therapy in lymphoma

video-image

Lori Leslie, MD, offers perspective on the role of umbralisib in relapsed/refractory lymphoma

video-image

John Mascarenhas, MD, on JAK inhibitors & combination therapies in myeloproliferative neoplasms

video-image

Lori Leslie, MD, considers the use of zanubrutinib in relapsed/refractory mantle cell lymphoma

video-image

John Mascarenhas, MD, on the role of molecular analysis in myeloproliferative neoplasms

video-image

Lori Leslie, MD, considers how physicians should be thinking about the use of BTK inhibitors in CLL

video-image

John Mascarenhas, MD, on the individualized management of myeloproliferative neoplasms

video-image

Lori Leslie, MD, offers her perspective on the latest treatment trends in aggressive lymphomas

video-image

Joshua Richter, MD, on the Phase 3 ICARIA-MM study from the 61st ASH Annual Meeting and Exposition

video-image

John Mascarenhas, MD, shares outcomes from the MANIFEST study examining CPI-0610 in myelofibrosis

video-image

Joshua Richter, MD, discusses the data investigating iberdomide presented at ASH 2019

video-image

Joshua Richter, MD, provides opinion on the role of BCMA CAR-T cells in the management of MM

video-image

Parameswaran Hari, MD, MRCP, offers his impression of the Phase 3 ICARIA-MM trial from ASH 2019

video-image

Joshua Richter, MD, regarding the Phase 3 CANDOR study in relapsed/refractory multiple myeloma

video-image

Parameswaran Hari, MD, MRCP, on novel combination treatment options & sequencing strategies in MM

video-image

Parameswaran Hari, MD, MRCP, considers the role of stem cell transplantation in myeloma

video-image

Parameswaran Hari, MD, MRCP, tells us about the design & outcomes of the STORM and Mammoth studies

video-image

Deepu Madduri, MD, explains how JNJ-4528 differs from other CAR-T products

video-image

Leslie Popplewell, MD, summarizes the role of checkpoint inhibitors in the treatment of lymphomas

video-image

Catherine Smith, MD, discusses prognostic factors and outcomes in acute myeloid leukemia

video-image

Leslie Popplewell, MD, on the role of CAR-T cell therapy in aggressive B-cell lymphomas

video-image

Catherine Smith, MD, offers her overall impression on the changing FLT3 inhibition landscape in AML

video-image

Leslie Popplewell, MD, considers the use of CAR-T cell therapies in aggressive B-cell lymphomas

video-image

Catherine Smith, MD, on whether all acute myeloid leukemia patients should be tested for FLT3

video-image

Leslie Popplewell, MD, considers whether there is sufficient evidence supporting bridging therapy

video-image

Deepu Madduri, MD, on how CAR-T cell therapy plays a role in the management of multiple myeloma

video-image

Catherine Smith, MD, tells us about the outcomes of the Phase 3 ADMIRAL trial presented at ASH 2019

video-image

Leslie Popplewell, MD, offers opinion on the next frontier in the development of CAR-T treatment

video-image

Deepu Madduri, MD, elaborates on the outcomes of the CARTITUDE-1 study

video-image

Saad Usmani, MD, FACP, considers data in smoldering MM coming out of ASCO 2019

video-image

Parameswaran Hari, MD, discusses the role of CAR-T therapy in multiple myeloma

video-image

Parameswaran Hari, MD, considers whether isatuximab will become a viable option in MM

video-image

Saad Usmani, MD, FACP, regarding outcomes from the MAIA study presented at ASCO 2019

video-image

Parameswaran Hari, MD, elaborates on the outcome from the ECOG trial in SMM

video-image

Robert M. Rifkin, MD, FACP, speculates on the promise of bispecific antibodies in MM

video-image

Robert M. Rifkin, MD, FACP, discusses maintenance regimens for multiple myeloma

video-image

Paul G. Richardson, MD, shares clinical results from the ECOG trial in smoldering MM

video-image

Robert M. Rifkin, MD, FACP, considers progression-free survival in MM when treating with isatuximab

video-image

Paul G. Richardson, MD, considers whether isatuximab shows promise as a treatment option for MM

video-image

Robert M. Rifkin, MD, FACP, explains how isatuximab differs from daratumumab

video-image

Paul G. Richardson, MD, considers progression-free survival in MM when treating with isatuximab

video-image

Robert M. Rifkin, MD, FACP, discusses outcomes from the ECOG trial in smoldering multiple myeloma

video-image

Paul G. Richardson, MD, regarding the updated FORTE trial data in multiple myeloma

video-image

Amrita Krishnan, MD, considers whether KRD will replace stem cell transplant

video-image

Amrita Krishnan, MD, discusses the future of isatuximab in the treatment of relapsed/refractory MM

video-image

Amrita Krishnan, MD, regarding outcomes from the CASSIOPEIA trial presented at ASCO '19

video-image

Amrita Krishnan, MD, tells us about the outcomes of the ECOG trial in SMM

video-image

Carol Moreno, MD, PhD, on the Phase 3 trial examining ibrutinib + rituximab versus FCR in CLL

video-image

Carol Moreno, MD, PhD, on how the outcomes of the illUMINTATE trial impact treatment of CLL

video-image

Jasmine Zain, MD, on the most exciting studies in lymphoma presented at ASH 2018

video-image

Yana Pikman, MD, regarding research outcomes from the LEAP Consortium

video-image

Jasmine Zain, MD, discusses novel treatment research regarding transplants at City of Hope

video-image

Jasmine Zain, MD, considers the impact of the new induction regimen in PTCL

video-image

Yana Pikman, MD, on the efforts of the LEAP Consortium in pediatric acute leukemia

video-image

Jasmine Zain, MD, defines successful induction regimens when treating PTCL

video-image

Jasmine Zain, MD, elaborates on the investigation of novel induction regimens in PTCL

video-image

Jasmine Zain, MD, regarding the standard of care in treatment of PTCL

video-image

Rod A. Humerickhouse, MD, PhD, describes recent advancements in the treatment of CLL

video-image

Rod A. Humerickhouse, MD, PhD, considers testing for minimal residual disease in CLL

video-image

Rod A. Humerickhouse, MD, PhD, on MRD as a surrogate marker in chronic lymphocytic leukemia

video-image

Jason Butler, PhD, considers how vascular integrity impacts the leukemia-initiating metabolic switch

video-image

Rena Feinman, PhD, considers the the role of the microbiome in cancer & response to therapy

video-image

Jason Butler, PhD, on how age-associated aberrant MAPK signaling impacts hematopoiesis

video-image

Rod A. Humerickhouse, MD, PhD, regarding potential side effects from venetoclax + rituximab in CLL

video-image

Sen Zhuang, MD, PhD, shares the research & development philosophy at Janssen

video-image

Rod A. Humerickhouse, MD, PhD, on treating CLL patients with venetoclax and rituximab

video-image

Sen Zhuang, MD, PhD, shares details from the LCAR-838M study in relapsed/refractory MM

video-image

Sen Zhuang, MD, PhD, speculates on how LCAR-838M may impact the treatment of MM

video-image

Sen Zhuang, MD, PhD, regarding the development of LCAR-B38M

video-image

Rod A. Humerickhouse, MD, PhD, elaborates on venetoclax in treatment of MM

video-image

Katja Weisel, MD, provides opinion on anti-BCMA CAR-T cell therapy in multiple myeloma

video-image

Habte Yimer, MD, considers the outcomes of the GRIFFIN study in multiple myeloma

video-image

Katja Weisel, MD, discusses current maintenance regimens in multiple myeloma

video-image

Habte Yimer, MD, speculates on the future of anti-BCMA CAR-T cell therapy

video-image

Keith Pratz, MD, considers emerging therapies for newly diagnosed or relapsed AML patients

video-image

Katja Weisel, MD, elaborates on the outcomes of the TOURMALINE-MM3 study

video-image

Habte Yimer, MD, regarding the POLLUX and CASTOR studies presented at ASH 2018

video-image

Sattva Neelapu, MD, speculates on the future of CAR-T therapies in lymphoma

video-image

Keith Pratz, MD, on genetic testing in AML prior to the start of therapy

video-image

Katja Weisel, MD, shares outcomes of the POLLUX and CASTOR studies from ASH 2018

video-image

Habte Yimer, MD, regarding the Lyra trial in newly diagnosed multiple myeloma presented at ASH 2018

video-image

Peter Vorhees, MD, describes what regimens are being used for multiple myeloma patients today

video-image

Peter Vorhees, MD, discusses the outcomes of the TOURMALINE-MM3 study in MM

video-image

Peter Vorhees, MD, discusses outcomes of the ALCYONE trial in multiple myeloma patients

video-image

Carol Moreno, MD, PhD, discusses MRD as a legitimate surrogate marker in CLL

video-image

Carol Moreno, MD, PhD, describes recent advancements in the treatment of CLL

video-image

Keith Pratz, MD, comments on the Phase I study of gilteritinib presented at ASH 2018

video-image

Carol Moreno, MD, PhD, shares outcomes from the iLLUMINATE trial presented at ASH 2018

video-image

Sattva Neelapu, MD, considers the use of axicabtagene ciloleucel with elderly lymphoma patients

video-image

Keith Pratz, MD, regarding the reliability of the companion diagnostic test for FLT3

video-image

Sattva Neelapu, MD, on real-world experience & clinical studies examining axicabtagene ciloleucel

video-image

Keith Pratz, MD, describes how gilteritinib fits into treatment algorithms for AML

video-image

Sattva Neelapu, MD, regarding the ZUMA-1 two-year follow-up study in DLBCL

video-image

James McCloskey, MD, elaborates on the role of molecular testing in newly diagnosed AML

video-image

Rafael Fonseca, MD, on the effectiveness of anti-BCMA CAR-T cell therapy in multiple myeloma

video-image

James McCloskey, MD, regarding molecular testing in acute myelogenous leukemia

video-image

Rafael Fonseca, MD, discusses maintenance regimens for multiple myeloma

video-image

James McCloskey, MD, considers the application of the FLT3 test in newly diagnosed AML patients

video-image

Rafael Fonseca, MD, regarding the TOURMALINE-MM3 study in multiple myeloma

video-image

James McCloskey, MD, describes how the FLT3 mutation influences treatment decisions in AML

video-image

Rafael Fonseca, MD, elaborates on the outcomes of the POLLUX and CASTOR studies in MM

video-image

James McCloskey, MD, speculates on the reliability of the companion diagnostic test for FLT3

video-image

Rafael Fonseca, MD, discusses frontline multiple myeloma treatment patterns

video-image

Edward Copelan, MD, considers the role of allogeneic transplantation in lymphoma & multiple myeloma

video-image

Edward Copelan, MD, regarding gilteritinib for patients with FLT3+ AML

video-image

Nikhil Munshi, MD, discusses the outcomes of the TOURMALINE-MM3 study in multiple myeloma

video-image

Nikhil Munshi, MD, discusses the POLLUX and CASTOR studies regarding the use of daratumumab in MM

video-image

Nikhil Munshi, MD, regarding the outcomes of the CA204-142 study from ASH 2018

video-image

Nikhil Munshi, MD, considers how ID2 function impacts oncogenesis in multiple myeloma

video-image

Andrew Pecora, MD, shares his thoughts on the necessity of allogeneic transplants to MML patients

video-image

Nizar Bahlis, MD, speculates on the future of anti-BCMA CAR-T cell therapy in MM

video-image

Nizar Bahlis, MD, describes current maintenance regimens for multiple myeloma

video-image

John Burke, MD, elaborates on the Beat AML umbrella study

video-image

Nizar Bahlis, MD, discusses the outcomes of the TOURMALINE-MM3 study from ASH 2018

video-image

John Burke, MD, comments on clinical research examining gilteritinib in newly diagnosed AML

video-image

Nizar Bahlis, MD, regarding the impact of the POLLUX and CASTOR studies from ASH 2018

video-image

John Burke, MD, elaborates on the incorporation of venetoclax into AML treatment regimens

video-image

Elizabeth Budde, MD, evaluates the clinical study investigating mosunetuzumab from ASH 2018

video-image

John Burke, MD, speaks to the reliability of the FLT3 mutation test

video-image

Elizabeth Budde, MD, on how City of Hope has overcome logistical hurdles associated with CAR-T

video-image

John Burke, MD, regarding gilteritinib in acute myeloid leukemia treatment

video-image

Elizabeth Budde, MD, discusses the role of CAR-T therapies in lymphoma treatment algorithms

video-image

Robert Rifkin, MD, shares his thoughts on if a rituximab biosimilar can replace rituximab

video-image

Robert Rifkin, MD, discusses the rationale for genetically profiling AML patients

video-image

Robert Rifkin, MD, discusses the outcomes of the TOURMALINE-MM3 study

video-image

Robert Rifkin, MD, talks about what clinical data could change the way multiple myeloma is treated

video-image

Ravi Vij, MD, on molecular testing and acute myelogenous leukemia

video-image

Samer Khaled, MD, tells us about the MEDALIST study examining myelodysplastic syndrome

video-image

Ravi Vij, MD, considers anti-BCMA CAR-T cell therapy in multiple myeloma

video-image

Ravi Vij, MD, discusses current maintenance regimens for multiple myeloma

video-image

Samer Khaled, MD, on incorporating venetoclax into treatment regimens for AML

video-image

Ravi Vij, MD, shares details regarding his clinical study presented at ASH 2018

video-image

Samer Khaled, MD, regarding gilteritinib in treatment of acute myelogenous leukemia

video-image

Samer Khaled, MD, shares details of his study examining the use of CAR-T therapy in ALL

video-image

Ravi Vij, MD, regarding the POLLUX and CASTOR clinical studies in multiple myeloma

video-image

Andrzej Jakubowiak, MD, shares thoughts on the POLLUX and CASTOR clinical studies

video-image

Andrzej Jakubowiak, MD, PhD, discusses maintenance regimens in treatment of multiple myeloma

video-image

Andrzej Jakubowiak, MD, PhD, regarding the ALCYONE trial presented at ASH 2018

video-image

Andrzej Jakubowiak, MD, discusses the outcomes of the GRIFFIN study from ASH 2018

video-image

Chadi Nabhan, MD, MBA, on the role of advanced practice practitioners

video-image

Chadi Nabhan, MD, MBA, shares what is being done to prevent oncologist burnout

video-image

Chadi Nabhan, MD, MBA, discusses the key factors contributing to physician burnout

video-image

Sundar Jagannath, MD, discusses the role of checkpoint inhibitors in treatment of MM

video-image

Sundar Jagannath, MD, regarding proteasome inhibitors in the treatment of MM

video-image

Maria-Victoria Mateos, MD, elaborates on the TOURMALINE-MM3 presented at ASH 2018

video-image

Maria-Victoria Mateos, MD, on the addition of daratumumab to revlimid/dexamethasone in MM

video-image

Sundar Jagannath, MD, considers maintenance regimens for multiple myeloma (MM) patients

video-image

Sundar Jagannath, MD, elaborates on the outcomes of CA204-142 in MM

video-image

Maria-Victoria Mateos, MD, regarding the CASTOR trial presented at ASH 2018

video-image

Maria-Victoria Mateos, MD, shares outcomes from the ALCYONE study in MM

video-image

Jeff Sharman, MD, shares his thoughts on rituximab biosimilars in follicular lymphoma

video-image

Lorenz Trumper, MD, discusses the results of ECHELON-2 in frontline PTCL

video-image

Jeff Sharman, MD, on the outcomes of CAPTIVATE study investigating ibrutinib and venetoclax

video-image

Jeff Sharman, MD, on how important the CLL-14 study is in determining CLL treatment strategies

video-image

Lorenz Trumper, MD, on the current standard of care for the frontline treatment of PTCL

video-image

Jeff Sharman, MD, discusses the phase 3 study investigating ibrutinib in younger CLL patients

video-image

Lorenz Trumper, MD, speaks on the differences between B-Cell and T-Cell lymphomas

video-image

Jeff Sharman, MD, discusses the phase 3 study investigating ibrutinib in older CLL patients

video-image

Swaminathan P. Iyer, MD, regarding improvements in the treatment of CTCL

video-image

Swaminathan P. Iyer, MD, shares exciting studies regarding the treatment of PTCL from ASH 2018

video-image

Swaminathan P. Iyer, MD, on the outcomes of the ECHELON-2 study in PTCL

video-image

Andre Goy, MD, comments on the long-term outcome of acalabrutinib in MCL

video-image

Andre Goy, MD, on immunotherapy and the treatment of hematologic malignancies

video-image

Andre Goy, MD, considers checkpoint inhibitors in hematologic malignancies

video-image

Andre Goy, MD, discusses his real-world experience using axi-cel CAR-T cell therapy

video-image

Andre Goy, MD, on research regarding the use of axi-cel CAR-T cell therapy in DLBCL

video-image

Tatyana Feldman, MD, regarding improvements in the treatment of CTCL

video-image

Tatyana Feldman, MD, on exciting studies from ASH 2018 regarding the treatment of PTCL

video-image

David Siegel, MD, explains the results of MM014 study presented at ASH

video-image

Julie Vose, MD, discusses improvements made in the delivery of CAR-T therapies in lymphoma

video-image

David Siegel, MD, discusses anti-BCMA CAR-T cell therapy for multiple myeloma patients

video-image

Frederick Locke, MD, discusses how to integrate CAR-T with stem cell transplant

video-image

Andre Goy, MD, on responses & outcomes when treating lymphoma with CAR-T therapies

video-image

Tatyana Feldman, MD, shares outcomes of the ECHELON-2 study in PTCL

video-image

David Siegel, MD, talks about the TOURMALINE-MM3 study and the treatment of multiple myeloma

video-image

Tatyana Feldman, MD, offers opinion on the ECHELON-2 study in PTCL

video-image

Frederick Locke, MD, on the use of CAR-T therapies in leukemia and lymphoma

video-image

Tatyana Feldman, MD, on unmet needs in peripheral T-cell lymphoma (PTCL)

video-image

Julie Vose, MD, on if CAR-T therapies are showing impressive results in lymphoma

video-image

Andrew Pecora, MD, tells us about the results of the CPIT trial presented here at ASH

video-image

David Siegel, MD, shares his thoughts on the daratumamab studies presented at ASH 2018

video-image

Julie Vose, MD, tells us about the results of the AUGMENT study in relapsed/refractory indolent NHL

video-image

Julie Vose, MD, discusses whether polatuzumab improves outcomes in DLBCL patients

video-image

Andre Goy, MD, discusses how CAR-T therapies are being integrated into the treatment of large B-Cell lymphoma

video-image

Ravi Vij, MD, on the outcomes of the TOURMALINE-MM3 study in multiple myeloma

video-image

Swaminathan Padmanabhan Iyer, MD, on if ECHELON-2 study is game changing for patients with PTCL

video-image

Keith Pratz, MD, discusses venetoclax in treatment of acute myeloid leukemia (AML)

video-image

James McClosky, MD, on using newly FDA approved gilteritinib for patients with AML

video-image

Peter Vorhees, MD, discusses the outcomes of the GRIFFIN trial in multiple myeloma

video-image

Noa Biran, MD, on combination carfilzomib & daratumumab in revlimid-refractory multiple myeloma

video-image

Noa Biran, MD, considers whether VPd is effective in relapsed multiple myeloma

video-image

Noa Biran, MD, on the logistics involved in delivering CAR-T in the BB2121 study

video-image

Noa Biran, MD, on the impact of the BB2121 study in multiple myeloma

video-image

Noa Biran, MD, shares some of the exciting clinical advances presented at ASCO 2018

video-image

Daniel J. DeAngelo, MD, PhD, offers his opinion on the clinical development of BLU-285

video-image

Daniel J. DeAngelo, MD, PhD, on the phase 1 study of BLU-285 in advanced systemic mastocytosis

video-image

Daniel J. DeAngelo, MD, PhD, discusses the mechanism of action of BLU-285 and what makes it unique

video-image

Andrew Lane, MD, PhD, describes the efficacy outcomes of SL-401 consolidation therapy in AML

video-image

Robert Soiffer, MD, discusses ways to enhance the activity of Il-2 in chronic GVHD

video-image

Ching-Hon Pui, MD, speculates on the use of CAR T-cell therapy in pediatric ALL patients

video-image

Ching-Hon Pui, MD, explains how precision medicine is changing the way pediatric ALL is treated

video-image

Ching-Hon Pui, MD, on whether the FDA should accept minimal residual disease as a surrogate endpoint

video-image

Ching-Hon Pui, MD, discusses minimal residual disease in pediatric and adult ALL patients

video-image

Jesus San-Miguel, MD, on the role of daratumumab in the front-line setting in multiple myeloma (MM)

video-image

Jorge Cortes, MD, shares data presented at ASH 2017 regarding bosutinib in CML treatment

video-image

Brad S. Kahl, MD, on the evidence for maintenance rituximab as a front-line treatment option in FLL

video-image

James R. Downing, MD, explains the mission of St. Jude Children’s Research Hospital

video-image

Andrew Lane, MD, PhD, on how frequently clinicians interact with frail AML patients

video-image

Andrew Lane, MD, PhD, on treatment approaches when managing frail AML patients

video-image

Andrew Lane, MD, PhD, offers strategies for clinicians when treating frail AML patient populations

video-image

Andrew Lane, MD, PhD, shares outcomes from the phase 2 study of SL-401 in patients with BPDCN

video-image

Jesus San-Miguel, MD, on daratumumab in a first-line setting as a result of the ALCYON study

video-image

Jesus San-Miguel, MD, explains the efficacy and safety outcomes of the ALCYON clinical study

video-image

Jens G. Lohr, MD, PhD, discusses the kind of information we can gather from liquid biopsy

video-image

Jens G. Lohr, MD, PhD, on utilizing liquid biopsy and how it compares to bone marrow biopsy

video-image

James Essell, MD, discusses the concerns for patients receiving allogeneic transplantations

video-image

James Essell, MD, on how allogeneic transplantation is incorporated into hematologic malignancy

video-image

Brad S. Kahl, MD, considers the unmet medical needs in treatment of Hodgkin lymphoma

video-image

Brad S. Kahl, MD, discusses the ECHELON-1 phase 3 clinical trial in Hodgkin lymphoma

video-image

Brad S. Kahl, MD, tells us about hi